PMID- 9122623
OWN - NLM
STAT- MEDLINE
DCOM- 19970422
LR  - 20190818
IS  - 0300-9475 (Print)
IS  - 0300-9475 (Linking)
VI  - 45
IP  - 3
DP  - 1997 Mar
TI  - Serum level of soluble interleukin-2 receptor in patients with seasonal allergic 
      rhinitis.
PG  - 315-21
AB  - The rate of release of the soluble form of interleukin-2 receptor (soluble IL-2R) 
      reflects T cell activation in vivo. Since T lymphocytes play a central role in 
      respiratory allergic disorders, the measurement of serum levels of soluble IL-2R 
      may be useful in analysing the disease state of allergic disorders. The study has 
      aimed at investigating the seasonal changes in serum soluble IL-2R in 81 patients 
      with seasonal allergic rhinitis due to Japanese cedar pollens, with special 
      reference to the effect of anti-allergic pharmacotherapy and immunotherapy. Serum 
      samples were obtained twice from each patient, before and during the pollen 
      season, and all the serum samples were simultaneously used for determination of 
      soluble IL-2R and cedar pollen-specific immunoglobin E (IgE). Seasonal elevation 
      in soluble IL-2R was not associated with the good clinical outcome but was 
      associated with the poor clinical outcome, irrespective of pharmacotherapy or 
      immunotherapy. Additionally, successful immunotherapy suppressed seasonal 
      elevation of serum soluble IL-2R more strongly than successful pharmacotherapy, 
      and seasonal increase rates in soluble IL-2R were inversely correlated with the 
      duration of immunotherapy. Seasonal increase rates in soluble IL-2R were 
      significantly correlated with seasonal increase rates in specific IgE in both the 
      medication group and the immunotherapy patients. These results may suggest that 
      seasonal changes in serum soluble IL-2R may serve as an indicator for clinical 
      outcome of seasonal allergic rhinitis, that the magnitude of T cell activation 
      could affect specific IgE production, and that T cell activation could be 
      gradually modulated as immunotherapy proceeds. In conclusion, seasonal changes in 
      serum soluble IL-2R may serve as an objective indicator for clinical outcome of 
      seasonal allergic rhinitis.
FAU - Ohashi, Y
AU  - Ohashi Y
AD  - Department of Otolaryngology, Osaka City University Medical School, Japan.
FAU - Tanaka, A
AU  - Tanaka A
FAU - Kakinoki, Y
AU  - Kakinoki Y
FAU - Ohno, Y
AU  - Ohno Y
FAU - Sakamoto, H
AU  - Sakamoto H
FAU - Kato, A
AU  - Kato A
FAU - Masamoto, T
AU  - Masamoto T
FAU - Wahio, Y
AU  - Wahio Y
FAU - Nakai, Y
AU  - Nakai Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
RN  - 0 (Receptors, Interleukin-2)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibody Specificity
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Middle Aged
MH  - Receptors, Interleukin-2/*blood
MH  - Rhinitis, Allergic, Seasonal/*blood/drug therapy/*immunology/therapy
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1046/j.1365-3083.1997.d01-392.x [doi]
PST - ppublish
SO  - Scand J Immunol. 1997 Mar;45(3):315-21. doi: 10.1046/j.1365-3083.1997.d01-392.x.